Bibliografía
- Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child 2003; 88: 375–378
- Baker CJ. Rench MA. Fernandez M. Paoletti LC. Kasper DL. Edwards MS. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. J Infect Dis 2003; 188: 66-73
- Brigtsen, AK, Kasper DL, Baker CJ, Jennings HJ, Guttormsen HK. Induction of cross-reactive antibodies by immunization of healthy adults with types Ia and Ib group B streptococcal polysaccharide-tetanus toxoid conjugate vaccines. J Infect Dis 2002; 185: 1277-1284
- CDC. Prevention of perinatal group B streptococcal disease. Revised Guidelines from CDC. MMWR 2002; 51 (RR11)
- Cheng Q, Carlson B, Pillai S, Eby R, Edwards L, Olmsted SB, Cleary P. Antibody against surface-bound C5a peptidase Is opsonic and initiates macrophage killing of group B streptococci. Infect Immun 2001; 69: 2302-2308
- Cheng Q, Debol S, Lam H, Eby R, Edwards L, Matsuka Y, et al. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of group B streptococci from lungs of infected mice. Infect Immun 2002; 70: 6409-6415
- Erdogan S, Fagan PK, Talay SR, Rohde M, Ferrieri P, Flores AE, et al. Molecular analysis of group B protective surface protein: a new cell surface protective antigen of group B streptococci. Infect Immun 2002; 70: 803-811
- Hughes MJ, Moore JC, Lane JD, Wilson R, Pribul PH, Younes ZN, et al. Identification of major outer surface proteins of Streptococcus agalactiae. Infect Immun 2002; 70: 1254-1259
- Larsson C, Stalhammar-Carlemalm M, Lindahl G. Protection against experimental infection with group B streptococcus by immunization with a bivalent protein vaccine. Vaccine 1999; 17: 454-458
- Paoletti LC, Rench MA, Kasper DL, Molrine D, Ambrosino D, Baker CJ. Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines. Infect Immun 2001; 69: 6696-6701
- Paoletti. L.C., Madoff, L.C., Vaccines to prevent neonatal GBS infection. Semin Neonatol 2002; 7: 315-323
- Paoletti, L.C., Kasper, D.L. Conjugate vaccines against group B streptococcus Types IV and VII. J Infect Dis 2002; 186: 123-126
- Paoletti LC, Peterson DL, Legmann R, Collier RJ. Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen. Vaccine 2001; 20: 370-376
- Rioux S, Denis Martin, Hans-Wolfgang Ackermann, Julie Dumont, Josée Hamel, and Bernard R. Brodeur. et al. Localization of surface immunogenic protein on group B streptococcus. Infect Immun 2001; 69: 5162-5165
- Schuchat, A. Group B streptococcus (Seminar). Lancet 1999; 353
- Shen X, Lagergard T, Yang Y, Lindblad M, Fredriksson M, Holmgren J. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization. Vaccine 2000; 19: 850-861
- Shen X, Lagergard T, Yang Y, Lindblad M, Fredriksson M, Wallerstrom G, et al. Effect of pre-existing immunity for systemic and mucosal immune responses to intranasal immunization with group B Streptococcus type III capsular polysaccharide-cholera toxin B subunit conjugate. Vaccine 2001; 19: 3360-3368
- Shen X, Lagergård T, Yang Y, Lindblad M, Fredriksson M, Holmgren J. Group B streptococcus capsular polysaccharide-cholera toxin B subunit conjugate vaccines prepared by different methods for intranasal immunization. Infect Immun 2001, 69: 297-306
